论文部分内容阅读
为延长抗癌药物在肝脏中存留时间并缓释。方法作者将１８例肝癌病人分成单纯阿霉素（ＡＤＭ）注射组〔ＡＤＭ单注组）、碘化油阿霉素（Ｌｉｐ－ＡＤＭ）组和羧甲基纤维素钠阿霉素（ＣＭＣ－ＡＤＭ）组，进行对照研究，测定各组肝静脉的血药浓度变化。结果ＡＤＭ单注组峰值较高（３．１ｕｇ／ｍｌ），下降迅速。Ｌｉｐ－ＡＤＭ和ＣＭＣ－ＡＤＭ两组峰值较低（０．９２和０．７５ｕｇ／ｍｌ），且延至５ｍｉｎ，下降缓慢，与ＡＤＭ单注组相比差异有显著性（Ｐ＜０．０５）。结论ＣＭＣ－ＡＤＭ在肝内有较好的缓释ＡＤＭ的作用，无栓塞作用，是ＴＡＩ病人较理想的药物载体
To prolong the duration of anticancer drugs in the liver and release them. METHODS: Eighteen patients with liver cancer were divided into a single adriamycin (ADM) injection group (ADM single injection group), Lipid-ADM (Lip-ADM) group, and sodium carboxymethyl cellulose (CMC-ADM). In the group, a controlled study was conducted to determine changes in plasma concentrations of hepatic veins in each group. Results The peak value of the ADM single injection group was higher (3.1ug/ml) and decreased rapidly. The peaks of Lip-ADM and CMC-ADM were lower (0.92 and 0.75 μg/ml), and they were slowed down to 5 minutes. The difference was statistically significant (P<0.05). Conclusion CMC-ADM has a good sustained release of ADM in the liver and no embolism. It is an ideal drug carrier for TAI patients.